Patents by Inventor Andrew Marcus
Andrew Marcus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250042673Abstract: Apparatus for sorting articles includes a conveyor having a plurality of article support members, each article support member provided to extend longitudinally parallel to a direction of movement of the conveyor, the support members being provided spaced 5 transversely across a conveyor and being pivotable at a first end about a transverse axis to unload the article from the conveyor.Type: ApplicationFiled: December 12, 2022Publication date: February 6, 2025Inventors: Hamish Alexander Nigel KENNEDY, Finn Marcus KENNEDY, Andrew David MCINTYRE
-
Publication number: 20230174541Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: ApplicationFiled: September 2, 2022Publication date: June 8, 2023Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
-
Patent number: 11535614Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: September 9, 2020Date of Patent: December 27, 2022Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 11479557Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: GrantFiled: April 1, 2020Date of Patent: October 25, 2022Assignee: VITAE PHARMACEUTICALS, LLCInventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
-
Patent number: 11459253Abstract: The present invention relates to systems and methods for removing and recovering precious metals, such as platinum-group metals (PGMs), including palladium, from wastewater and waste streams. The invention also relates to systems and methods for recycling the recovered precious metals for catalytic applications.Type: GrantFiled: February 2, 2017Date of Patent: October 4, 2022Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: Chen Zhou, Andrew Marcus, Bruce Rittmann, Zhaocheng Wang, Aura Ontiveros-Valencia, Rosa Krajmalnik-Brown
-
Publication number: 20210401532Abstract: A protective equipment includes a rotatable window and an extended member secured to a peripheral edge of the rotatable window. The rotatable window may be configured as a shield to be disposed between a patient and a healthcare worker to minimize exposure of the healthcare worker to at least one of the patient's bodily fluids, bacteria, and viruses. A port provides entrance by one or more instruments through the rotatable window or the extended member, thereby providing access to the patient while protecting the healthcare worker from the patient's bodily fluids, bacteria and/or viruses. The protective equipment may include an air flow system configured to receive and filter air expelled by the patient, to pull the expelled air away from the patient's face and to filter/clean the expelled air.Type: ApplicationFiled: June 24, 2021Publication date: December 30, 2021Applicant: LevMarc LLCInventors: Steven Brian Levine, Andrew Marcus
-
Patent number: 11155135Abstract: A traction system is provided for a rail draft vehicle including an engine with a driveshaft, at least a pair of rubber-tired traction wheels, and at least one rail guide wheel pressurized relative to the vehicle by at least one fluid-powered cylinder. Included in the system are a programmable processor connected to a driveshaft speed sensor, a rail guide wheel speed sensor, an engine throttle controller, a fluid-powered cylinder controller and a vehicle control panel. The processor is constructed and arranged for automatically adjusting the engine throttle controller in coordination with the fluid-powered cylinder controller for achieving movement of the rail draft vehicle from a dead stop position by increasing applied vehicle weight upon the traction wheels by the at least one fluid-powered cylinder and adjusting engine RPM's until the vehicle begins movement as detected by the rail guide wheel speed sensor.Type: GrantFiled: April 26, 2019Date of Patent: October 26, 2021Assignee: NORDCO INC.Inventors: Michael Terrence Blouin, Andrew Marcus Noyes, Lee William Campbell, Joel Wesley Frank, Eric John Slocombe
-
Publication number: 20210238174Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: ApplicationFiled: September 9, 2020Publication date: August 5, 2021Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Publication number: 20210179463Abstract: The present invention relates to systems and methods for removing and recovering precious metals, such as platinum-group metals (PGMs), including palladium, from wastewater and waste streams. The invention also relates to systems and methods for recycling the recovered precious metals for catalytic applications.Type: ApplicationFiled: February 2, 2017Publication date: June 17, 2021Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Chen Zhou, Andrew Marcus, Bruce Rittmann, Zhaocheng Wang, Aura Ontiveros-Valencia, Rosa Krajmalnik-Brown
-
Patent number: 11001583Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: April 25, 2019Date of Patent: May 11, 2021Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Linghang Zhuang
-
Publication number: 20210090011Abstract: Disclosed is a system for identifying and tracking items using unique product identifiers. In some embodiments, the system includes a central unit and an external unit. The central unit is coupled to the external unit. The external unit includes a plurality of products. The central unit is configured to generate a plurality of unique product identifiers (IDs). The central unit is further configured to authorize the external unit to access the plurality of unique IDs. Upon authorizing, the central unit accesses the plurality of unique IDs and assigns each of the plurality of unique IDs to a product of a plurality of products.Type: ApplicationFiled: September 25, 2019Publication date: March 25, 2021Inventor: Andrew Marcus Fletcher Rae
-
Publication number: 20210053974Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: ApplicationFiled: April 1, 2020Publication date: February 25, 2021Applicant: VITAE PHARMACEUTICALS, LLCInventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
-
Publication number: 20200339566Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: ApplicationFiled: January 24, 2020Publication date: October 29, 2020Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 10807980Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: July 9, 2019Date of Patent: October 20, 2020Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 10683302Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: GrantFiled: June 8, 2017Date of Patent: June 16, 2020Assignee: VITAE PHARMACEUTICALS, LLCInventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
-
Publication number: 20200172535Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: ApplicationFiled: July 9, 2019Publication date: June 4, 2020Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Publication number: 20200079767Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: ApplicationFiled: April 25, 2019Publication date: March 12, 2020Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Linghang Zhuang
-
Publication number: 20190375257Abstract: A traction system is provided for a rail draft vehicle including an engine with a driveshaft, at least a pair of rubber-tired traction wheels, and at least one rail guide wheel pressurized relative to the vehicle by at least one fluid-powered cylinder. Included in the system are a programmable processor connected to a driveshaft speed sensor, a rail guide wheel speed sensor, an engine throttle controller, a fluid-powered cylinder controller and a vehicle control panel. The processor is constructed and arranged for automatically adjusting the engine throttle controller in coordination with the fluid-powered cylinder controller for achieving movement of the rail draft vehicle from a dead stop position by increasing applied vehicle weight upon the traction wheels by the at least one fluid-powered cylinder and adjusting engine RPM's until the vehicle begins movement as detected by the rail guide wheel speed sensor.Type: ApplicationFiled: April 26, 2019Publication date: December 12, 2019Inventors: Michael Terrence BLOUIN, Andrew Marcus NOYES, Lee William CAMPBELL, Joel Wesley FRANK, Eric John SLOCOMBE
-
Patent number: 10399976Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: July 2, 2018Date of Patent: September 3, 2019Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Publication number: 20190144459Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: ApplicationFiled: June 8, 2017Publication date: May 16, 2019Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston